GALT Investors Have Opportunity to Join Galectin Therapeutics Inc. Fraud Investigation with the Schall Law Firm

Core Viewpoint - The Schall Law Firm is investigating Galectin Therapeutics Inc. for potential violations of securities laws related to misleading statements and failure to disclose important information to investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Galectin issued false or misleading statements regarding its development program for belapectin, an investigational galectin-3 inhibitor [2]. - On December 19, 2025, Galectin announced that the FDA provided a written response to its Type C meeting request, which was initially sought as an in-person or teleconference meeting [2]. - Following the announcement, Galectin's shares experienced a significant decline of 28.9% on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who suffered losses are encouraged to contact the firm for a free discussion of their rights [3].